Zusammenfassung
Obwohl viele Patientinnen mit Mammakarzinom in den Stadien I oder II mit Hilfe moderner chirurgischer, strahlentherapeutischer und adjuvanter internistisch-onkologischer Methoden von ihrer Erkrankung prinzipiell geheilt werden können, entwickeln etwa 40% aller Patientinnen mit Mammakarzinom eine metastasierende Erkrankung. Angesichts der Tatsache, daß es sich beim Mammakarzinom um einen sehr häufigen Tumor handelt — derzeit tritt die Erkrankung bei etwa jeder zehnten Bürgerin der Vereinigten Staaten von Amerika auf —, ist das Problem der Behandlung des metastasierenden Mammakarzinoms von großer klinischer Relevanz. Trotz einer breiten Palette von zur Verfügung stehenden Chemo- und Hormontherapeutika ist es aber bis jetzt nicht möglich, das metastasierende Mammakarzinom zu heilen, sodaß davon ausgegangen werden muß, daß die Metastasierung bei allen Patientinnen früher oder später zum Tod führt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Henderson IC (1984) Chemotherapy for advanced disease. In: Bonadonna G (ed) Breast cancer: diagnosis and management. Wiley, Chichester New York Brisbane Toronto Singapore, p 247
Dunphy FR, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207
Greenspan EM (1965) Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 33: 1
Cooper R (1969) Combination cytotoxic chemotherapy in hormone resistant breast cancer. Proc AACR 10: 15
Broder LE, Tormey DC (1974) Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev 1: 183
Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiamine platinum (cisDDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108
Carbone PP, Davis TE (1978) Medical treatment for advanced breast cancer. Semin Oncol 4: 417
Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1: 131
Davidson NE, Lippman ME (1988) Treatment of metastatic breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and management of breast cancer. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 375
Pötzi P, Zielinski C, Kühböck J (1985) Mitoxantrone in the treatment of advanced solid tumors. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo
Henderson IC, Allegra JC, Woodcock T, et al (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560
Chlebowski RT, Irwin LE, Pugh RP, et al (1979) Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39: 4503
Zielinski CC (1991) Zytostatische Chemotherapie. In: Grabner G, Geyer G (Hrsg) Innere Medizin. Maudrich, Wien (in Druck)
Canellos GP, Pocock SJ, Taylor SG III, et al (1976) Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882
Mouridsen HT, Palshof T, Brahm M, et al (1977) Evaluation of single drug versus multiple drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61: 47
Rubens RD, Knight RK, Hayward JL (1975) Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32: 730
Carmo-Pereira J, Costa FO, Henriques E (1980) Single drug versus combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer 16: 1621
Muss HB, White DR, Cooper MR, et al (1977) Combination chemotherapy in advanced breast cancer: a randomized trial comparing a three-versus a five-drug program. Arch Intern Med 137: 1711
Brunner KW, Sonntag RW, Martz G, et al (1975) A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36: 1208
Kennealey GT, Boston B, Mitchell MS, et al (1978) Combination chemotherapy for advanced breast cancer. Two regimens containing adriamycin. Cancer 42: 27
Trannum BL, McDonald B, Thigpen T, et al (1982) Adriamycin combinations in advanced breast cancer. Cancer 49: 835
Tormey DC (1975) Adriamycin in breast cancer: an overview of studies. Cancer Chemother Rep 6: 319
Hoogstraten B, George SL, Samal B, et al (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13
French Epirubicin Study Group (1988) A prospective randomized phase Ill trial comparing combination chemotherapy with cyclophosphamide, 5-fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 4: 679
Italian multicenter breast study with epirubicin (1988) Phase III randomized study of 5-fluorouracil, epirubicin and cyclophosphamide versus 5-fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicenter trial. J Clin Oncol 6: 972
Kührer I, Ludwig H, Scheithauer W, et al (1987) Cyclophosphamid, Mitoxantron, 5-Fluorouracil und Prednisolon als Kombinationstherapie beim metastasierten Mammakarzinom. FAC 6–9: 1415
Manni A, Pearson OH, Brodkey J, et al (1979) Transphenoidal hypophysectomy in breast cancer. Evidence for an individual role of pituary and gonadal hormones in supporting tumor growth. Cancer 44: 2330
Tormey DC, Gelman R, Band PR, et al (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235
Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625
Ahmann DL, O’Fallon J, O’Connell MJ, et al (1978) Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clin Trials 5: 219
Brambilla C, DeLena M, Rossi A, et al (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1: 801
Eagan RT, Ahmann DL, Edmonson JH, et al (1975) Controlled evaluation of the combination of adriamycin (NSC-123127), vincristine (NSC-67574), and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother Rep 6: 339
Irwin LE, Chlebowski RT, Weiner JM, et al (1980) Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial. Cancer Treat Rep 64: 981
Nemoto T, Horton J, Simon R, et al (1982) Comparison of four combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU, and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 49: 1988
Rainey JM, Jones SE, Salmon SE (1979) Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide. Cancer 43: 66
Tranum B, Hoogstraten B, Kennedy A, et al (1978) Adriamycin in combination for metastatic breast cancer. Cancer 41: 2078
Aisner J, Weinberg V, Perloff M, et al (1987) Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5: 1523
Bull JM, Tormey DC, Li SH, et al (1978) A randomized trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649
Muss HB, White DR, Richards F, et al (1978) Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141
Smalley RV, Lefante J, Bartolucci A, et al (1983) A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3: 209
Cunnings FJ, Gelmans R, Horton J (1985) Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 3: 932
Tormey DC, Weinberg VE, Leone LA, et al,(1984) A comparison of intermittent vs continuous and adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7: 231
Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and CTX-MTX-5FU-VCR-P (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625
Tormey DC, Lippman ME, Edwards BK, et al (1978) Evaluation of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy regimens for breast cancer. Proc AACR-ASCO 19: abstract #54
Hryniuk W, Bush H (1987) The importance of dose intensity in chemotherapy of metastatic breast cancer. Semin Oncol 4: 3
Bonadonna G, Valagussa P (1987) Dose response effect of CMF in breast cancer. Semin Oncol 1: 34
Hortobagyi G, Bodey G, Rodriguez V, et al (1987) Evaluation of high dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 3: 354
Jones R, Holland J, Strashun A, et al (1987) A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 2: 172
Williams SF, Mick R, Desser R, et al (1989) High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824
Wallerstein R, Spitzer G, Dunphy F, et al (1990) A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8: 1782
Smalley RV, Murphy S, Huguley CM Jr, et al (1976) Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36: 3911
Coates A, Gebski V, Bishop JF, et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490
Plotkin D, Waugh WJ (1983) Discontinuous chemotherapy for advanced breast cancer. Am J Clin Oncol 6: 375
Hall TC, Dederick MM, Nevinney HB, et al (1963) Prognostic value of response of patients with breast cancer to therapeutic castration. Cancer Chemother Rep 31: 47
Lewison EF (1965) Castration in the treatment of advanced breast cancer. Cancer 18: 1558
Stoll BA (1972) Castration and estrogen therapy. In: Stoll BA (ed) Endocrine therapy in malignant disease. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 117
Manni A, Santen R, Harvey H, et al (1986) Treatment of breast cancer with gonadotropin-releasing hormone. Endocrinol Rev 7: 89
Moore FD, Van Devanter SB, Boyden CM, et al (1974) Adrenalectomy with chemotherapy in the treatment of advanced breast cancer. Objective and subjective response rates: duration and quality of life. Surgery 76: 376
Silverstein MJ, Byron RL, Yonemoto RH, et al (1975) Bilateral adrenalectomy for advanced breast cancer: a 21 year experience. Surgery 77: 825
Schmidt M, Nemoto T, Dao T, et al (1971) Prognostic factors affecting adrenalectomy in patients with metastatic cancer of the breast. Cancer 27: 1106
Kaufmann M, Schmid H, Kiesel L, et al (1988) GnRH-Agonisten (Zoladex)-Therapie bei prämenopausalen Frauen mit metastasierendem Mammakarzinom. Geburtshilfe Frauenheilkd 48: 528
Williams MR, Walker KJ, Turkes A, et al (1986) The use of a LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 692
Kaufmann M, Jonat W, Kleeberg U, et al (1989) Goserelin, a depot gonadotropinreleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113
Preis P, Langer M, Kubista E, et al (1988) Decapeptyl als therapeutische Alternative beim metastasierenden Mammakarzinom prämenopausaler Patientinnen. Acta Med Austriaca 15: 78
Harper MJK, Walpole AL (1967) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13: 101
Jordan VC (1976) Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60: 1409
Jordan VC (1988) Chemosuppression of breast cancer with tamoxifen — laboratory evidence and future clinical investigation. Cancer Invest 6: 589
Jordan VC (1986) Estrogen/antiestrogen action and breast cancer therapy. Madison, University of Wisconsin
Jordan VC (1984) Biochemical pharmacology of antiestrogenic action. Pharmacol Rev 36: 245
Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127
Osborne CK, Boldt DH, Clark GM, et al (1983) Effects of tamoxifen in human breast cancer cell kinetics: accumulation of cells in early GI phase. Cancer Res 43: 3583
Sutherland RN, Green MD, Hall RE, et al (1983) Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the GO/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615
Bénry J, Green BJ, Matheson DS (1987) Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer. Eur J Cancer Clin Oncol 23: 517
Patterson JS, Battersby LA, Edwards DG (1982) Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocr Rel Cancer [Suppl 9]: 563
Legha S, Muggia FM (1976) Antiestrogens in the treatment of cancer. Ann Intern Med 84: 751
Mouridsen H, Palshof T, Patterson J (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rep 62: 131
Heel RC, Brogden RN, Speight TM, et al (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1
Pearson OH, Manni A, Arafah BM (1982) Antiestrogen treatment of breast cancer: an overview. Cancer Res 42: 3424
Pritchard KI, Thomson DB, Myers RE, et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787
Pritchard I, Meakin JW, Sawka C, et al (1985) The role and mechanism of action of tamoxifen in premenopausal women with metastatic carcinoma of the breast. Proc ASCO 4: 54 (abstract # C-206)
Hoogstraten B, Fletcher WS, Gad-el-Mawla N, et al (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 42: 4788
Planting A, Wijst JM, Alexieva-Figuseh J (1983) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Proc 3rd EORTC Breast Cancer Conference 9: 17 (abstract)
Tormey DC, Lippman ME, Edwards BK (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139
Asbury RF, Bakemeier RF, Folsch E, et al (1981) Treatment of metastatic breast cancer with aminoglutethimide. Cancer 47: 1954
Griffiths CT, Hall TC, Saba Z, et al (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31
Smith IE, Fitzharris BM, McKinna JA, et al (1978) Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 11: 646
Wells SA Jr, Santen RJ, Lipton A, et al (1978) Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187: 475
Kühböck J, Ludwig H, Pötzi P, et al (1985) Aminoglutethimidtherapie beim fortgeschrittenen Mammakarzinom. Wien Med Wochenschr: 608
Brodie AMH, Garrett WM, Hendrickson JR, et al (1983) Aromatase inhibitors, their pharmacology and application. J Steroid Biochem 19: 53
Coombes RC, Dowsett M, Goss P, et al (1984) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet i:1237
Coombes RC, Goss PE, Dowsett M, et al (1987) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Tumor Diagnostik & Therapie 8: 271
Dowsett M, Goss PE, Powles TJ, et al (1987) Use of the aromatase inhibitor 4hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 47: 1957
Goss PE, Powles TJ, Dowsett M, et al (1986) Treatment of advanced premenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46: 4823
Höffken K, Jonat W, Possinger K, et al (1990) Aromatase inhibition with 4hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8: 875
Bojar H (1983) Die Entwicklung der Rezeptorforschung, insbesondere in bezug auf die hochdosierte MAP-Therapie. In: Nagel GA, Robustelli del la Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 23
Lang I, Zielinski CC, Tempi H, et al (1990) Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor. Cancer 66: 1949
Cavalli F, Goldhirsch A, Jungi F, et al (1983) Eine randomisierte Studie zum Vergleich einer niedrigdosierten gegenüber einer hochdosierten Medroxyprogesteronazetat-Therapie bei der Behandlung von postmenopausalen Patientinnen mit fortgeschrittenem Mammakarzinom. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 147
Bumma C (1983) Metastasierendes Mammakarzinom auf Medroxyprogesteronazetat (MAP) und Hormonrezeptoren. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 97
Mattson W (1983) Die Behandlung des fortgeschrittenen Mammakarzinoms mit hochdosiertem Medroxyprogesteronazetat (HD-MAP). In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 139
Pannuti F, Martoni A, Lenaz C, et al (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62: 499
Robustelli della Cuna G, Caiciati A, Bernardo Strada MR, et al (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose response evaluation. Tumori 64: 143
De Lena M, Brambilla C, Valagussa P, et al (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175
Ahmann DL, O’Connell MJ, Hahn RG, et al (1977) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 297: 356
Cavalli F, Beer M, Martz G, et al (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J 2: 865
Falkson G, Falkson HC, Glidewell O, et al (1979) Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 43: 2215
Lloyd RE, Jones SE, Salmon SE (1979) Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer 43: 60
Ahmann DL, Green SJ, Bisel HF, et al (1982) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 5: 355
Cocconi G, DelLisi V, Boni C, et al (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51: 581
Brunner KW, Sonntag RW, Alberto P, et al (1977) Combined chemo-and hormonal therapy in advanced breast cancer. Cancer 39: 2923
Rubens RD, Begent RHJ, Knight RK, et al (1978) Combined cytotoxic and progestagen therapy for advanced breast cancer. Cancer 42: 1680
Mouridsen HT, Palshof T, Engelsman E, et al (1980) CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Eur J Cancer 1 [Stipp!’: 119
Mouridsen HT, Rose C, Engelsman E, et al (1985) Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC Breast Cancer Cooperative Group study of CMF versus CMF plus tamoxifen. Eur J Cancer Clin Oncol 21: 291
Lippman ME, Cassidy J, Wesley M, et al (1984) A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 2: 28
Allegra JC, Woodcock TM, Richman SP, et al (1982) A phase II trial of tamoxifen, premarin, methotrexate, and 5-fluorouracil in metastatic breast cancer. Breast Cancer Treat Rep 2: 93
Bowman D (1983) A phase II evaluation of sequential tamoxifen, premarin, methotrexate, and 5-fluorouracil in refractory stage IV breast cancer. Proc ASCO 2: 106 (abstract)
Kührer I, Gisslinger H, Scheithauer W, et al (1990) Conventional versus cytokinetic polychemotherapy in patients with advanced breast cancer: a randomized phase Ill study. Blut 61: 336 (abstract # A 55)
Nash CH, Jones SE, Moon TE, et al (1980) Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46: 2380
Mohla S, Sampson CC, Khan T, et al (1982) Estrogen and progesterone receptors in breast cancer in black Americans. Cancer 50: 552
Swenerton KD, Legha SS, Smith T, et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552
Decker DA, Ahmann DL, Bisel HF, et al (1979) Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA 242: 2075
Valagussa P, Brambilla C, Bonadonna G (1979) Advanced breast cancer. Are the traditional stratification parameters still of value when patients are treated with combination chemotherapy? Eur J Cancer 15: 565
Bull JM, Tormey DC, Li SH, et al (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649
George SL, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60: 731
Corle DK, Sears ME, Olson KB (1984) The relationship of quantitative estrogen receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer: an extramural analysis. Cancer 54: 1554
Mörz R, Francesconi M, Schemper M, et al (1982) The value of prognostic parameters for the stratification of advanced breast cancer patients. J Cancer Res Clin Oncol 102: 289
Tormey DC, Falkson G, Simon RM, et al (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247
DeWys WD, Begg C, Band P, et al (1981) The impact of malnutrition on treatment results in breast cancer. Cancer Treat Rep 65: 87
Derogatis LR, Abeloff MD, Melisaratos N (1979) Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242: 1504
Cassileth BR, Lusk EJ, Miller DS, et al (1985) Psychosocial correlates of survival in advanced malignant disease? N Engl J Med 312: 1551
Coburn J, Ahmann FR, Moon T, et al (1983) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 3: 303
Valagussa P, Rossi A, Tancini G, et al (1985) Is there any effective salvage treatment for relapsing operable breast cancer with N+? Proc ASCO 4: 56 (abstract # C-215)
Bitran JD, Desser RK, Shapiro CM, et al (1983) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51: 381
Buzdar AU, Legha SS, Hortobagyi GN, et al (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47: 2798
Preda F, Oriana S, Perozziello F, et al (1982) Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients. Tumori 68: 1982
Oberfield RA, Cady B, Pazianos AG, et al (1979) Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. Surg Gynecol Obstet 148: 881
Kiang DT, Kennedy BJ (1981) Chemoendocrine therapy in advanced breast cancer. Breast Cancer Res Treat 1: 105
Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111
Legha SS, Buzdar AU, Smith TL, et al (1980) Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438
Chang JC, Wegowske G (1981). Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. Cancer 48: 2503
Cocconi G, DeLisi V, Mori P, et al (1982) Estrogen receptors and response to chemotherapy in advanced breast cancer. Tumori 68: 67
Jonat W, Maas H, Stolzenbach G, et al (1980) Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 46: 2809
Rubens RD, Hayward JL (1980) Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922
Hilf R, Feldstein ML, Savlov ED, et al (1980) The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797
Hilf R, Feldstein ML, Gibson SL, et al (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993
Samal BA, Brooks SC, Cummings G, et al (1980) Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925
Young PCM, Ehrlich CE, Einhorn LH (1980) Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 46: 2961
Kiang DT, Frenning DH, Gay J, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46: 2814
Kiang DT, Frenning DH, Goldman Al, et at (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330
Lippman ME, Allegra JC, Thompson EB, et al (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223
Mortimer J, Reimer R, Greenstreet R, et at (1981) Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 65: 763
Rosenbaum C, Marsland TA, Stolbach LL, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer: the Tufts-Shattuck-Pondville experience. Cancer 46: 2919
Samann NA, Buzdar AU, Aldinger KA, et at (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554
Bloom ND, Tobin EH, Schreibman B, et at (1980) The role of progesterone receptors in the management of advanced breast cancer. Cancer 45: 2992
Osborne C, Yochmowitz M, Knight W, et at (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884
Rozenczweig M, Staquet MJ, VonHoff DD, et at (1979) Prognostic factors for the response to chemotherapy in advanced breast cancer. Cancer Clin Trials 2: 165
Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4: 237
Spiegel D, Kraemer HC, Bloom JR, et al (1989) Effect of psychological treatment on survival of patients with metastatic breast cancer. Lancet 1: 888
Rights and permissions
Copyright information
© 1992 Springer-Verlag/Wien
About this chapter
Cite this chapter
Zielinski, C. (1992). Therapie des metastasierenden Mammakarzinoms. In: Mammakarzinom. Angewandte Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7615-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-7091-7615-3_9
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82313-2
Online ISBN: 978-3-7091-7615-3
eBook Packages: Springer Book Archive